Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease, Healthy Volunteer

In brief

The primary objective of the study is to evaluate the safety and tolerability of single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants with Alzheimer's disease (AD). A secondary objective of the study for both healthy volunteers and participants with AD is to assess the serum pharmacokinetic(s) (PK) profile of BIIB076 after single-dose administration. Another secondary objective is to evaluate the immunogenicity of BIIB076 in serum after single-dose administration.

Key facts

Study ID

NCT03056729

Run by

Biogen

People needed

46

Starts

2017-02-17

Expected to finish

2020-03-03

Last updated by the study team

2020-03-24

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• MD Clinical — Hallandale, Florida, United States
• Bioclinica Research — Orlando, Florida, United States
• Progressive Medical Research — Port Orange, Florida, United States
• Hawaii Pacific Neuroscience — Honolulu, Hawaii, United States
• Indiana University — Indianapolis, Indiana, United States
• St Louis Clinical Trial — St Louis, Missouri, United States
• Covance Dallas CRU — Dallas, Texas, United States
• Covance CRU — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.